0.6196

6.08% 0.0355

After Hours: .59 -0.0296 -4.78%

VolitionRX Ltd (VNRX)

Overview News Price History Option Chain Discussions Forecast

VolitionRX Ltd stock is traded at $0.6196, with a volume of 104.58K. It is up +6.08% in the last 24 hours and down -3.02% over the past month. VolitionRX Limited, a life sciences company, engages in the development of blood tests to help diagnose a range of cancers worldwide. The company develops 39 epigenetic Nu.Q blood assays based on its Nucleosomics biomarker discovery platform. VolitionRX Limited is based in Singapore.

Previous Close:

$0.5841

Open:

$0.608

24h Volume:

104.58K

Relative Volume:

0.41

Market Cap:

$59.46M

Revenue:

$1.29M

Net Income/Loss:

$-29.87M

P/E Ratio:

-1.7211

EPS:

-0.36

Net Cash Flow:

$-14.70M

1W Performance:

-0.86%

1M Performance:

-3.02%

6M Performance:

+8.13%

1Y Performance:

-44.75%

1-Day Range:

$0.5778

$0.64

1-Week Range:

$0.566

$0.64

52-Week Range:

$0.4301

$1.22

VolitionRX Ltd Stock (VNRX) Company Profile

Name

VolitionRX Ltd

Sector

Healthcare (1177)

Industry

Diagnostics & Research (60)

Phone

646 650 1351

Address

No. 24-05 Shaw Centre, 1 Scotts Road, Singapore, TX

Employee

Twitter

@VolitionRx

Next Earnings Date

2024-11-12

Latest SEC Filings

VNRX's Discussions on Twitter

Compare VNRX with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
VNRX VolitionRX Ltd	0.6196	59.46M	1.29M	-29.87M	-14.70M	-0.36
TMO Thermo Fisher Scientific Inc	572.71	219.06B	42.88B	6.34B	7.27B	16.53
DHR Danaher Corp	210.01	151.02B	23.88B	3.90B	5.30B	5.28
A Agilent Technologies Inc	147.64	42.12B	6.51B	1.29B	1.37B	4.42
IQV Iqvia Holdings Inc	209.96	38.11B	15.32B	1.41B	1.96B	7.62
IDXX Idexx Laboratories Inc	460.56	37.71B	3.84B	866.24M	792.60M	10.37

VolitionRX Ltd Stock (VNRX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-01-23	Downgrade	The Benchmark Company	Buy → Hold
Feb-17-22	Resumed	Cantor Fitzgerald	Overweight
Mar-10-21	Initiated	Cantor Fitzgerald	Overweight
May-16-18	Initiated	Maxim Group	Buy
May-14-18	Reiterated	The Benchmark Company	Buy
Sep-07-16	Reiterated	Rodman & Renshaw	Buy
Feb-01-16	Initiated	Rodman & Renshaw	Buy

View All

VolitionRX Ltd Stock (VNRX) Latest News

Jan 30, 2025

Game-Changing Sepsis Detection: 971-Patient Study Validates Revolutionary Blood Test - StockTitan

Jan 30, 2025

Jan 10, 2025

D. Boral Capital Reiterates Buy Rating for VolitionRx (NYSE:VNRX) - Defense World

Jan 10, 2025

Jan 08, 2025

VolitionRx reports expanded global reach in 2024 - Investing.com India

Jan 08, 2025

VolitionRx's Nu.Q® Vet Cancer Test Hits Major Milestone: 110,000+ Tests Sold Across 20 Countries - StockTitan

Jan 08, 2025

Dec 22, 2024

VolitionRx (NYSE:VNRX) Coverage Initiated at StockNews.com - Defense World

Dec 22, 2024

Dec 14, 2024

StockNews.com Begins Coverage on VolitionRx (NYSE:VNRX) - Defense World

Dec 14, 2024

Dec 11, 2024

VolitionRx CEO Cameron John Reynolds acquires $79,999 in stock By Investing.com - Investing.com Nigeria

Dec 11, 2024

Dec 10, 2024

Volitionrx director Innes buys $99,999 in common stock By Investing.com - Investing.com Australia

Dec 10, 2024

Volitionrx director Innes buys $99,999 in common stock - Investing.com India

Dec 10, 2024

VolitionRx chief scientific officer Micallef acquires $24,999 in stock By Investing.com - Investing.com Australia

Dec 10, 2024

VolitionRx announces $1.9 million stock sale By Investing.com - Investing.com Australia

Dec 06, 2024

VolitionRx Secures $1.9M Financing with Insider Backing, Includes Strategic Warrant Package - StockTitan

Dec 06, 2024

Dec 04, 2024

VNRX: VolitionRx Reports 3Q 2024 results. Over 110,000 Nu.Q Canine Cancer tests have been sold. Cost cutting continues in a plan to be cash flow neutral in 2025. Management focused on signing licensing deals for Capture-PCR & Nu.Q NETs. - Zacks Small Cap Research

Dec 04, 2024

Dec 02, 2024

VolitionRx: Big EU Trials On Deck - Investing.com

Dec 02, 2024

Nov 28, 2024

VolitionRx (NYSE:VNRX) Coverage Initiated by Analysts at StockNews.com - Defense World

Nov 28, 2024

Nov 23, 2024

Benchmark Reaffirms Hold Rating for VolitionRx (NYSE:VNRX) - MarketBeat

Nov 23, 2024

Nov 20, 2024

VolitionRx Limited Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com

Nov 20, 2024

Nov 16, 2024

VolitionRx Limited (AMEX:VNRX) Q3 2024 Earnings Call Transcript - Insider Monkey

Nov 16, 2024

VolitionRX: Q3 Earnings Snapshot - New Haven Register

Nov 16, 2024